130 related articles for article (PubMed ID: 37673011)
1. Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers.
Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk AA; Husein DZ; Ibrahim IM; Elhendawy MA; Godfrey M; Metwaly AM
Comput Biol Chem; 2023 Dec; 107():107953. PubMed ID: 37673011
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
[TBL] [Abstract][Full Text] [Related]
3. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
4. Design, Molecular Modeling, MD Simulations, Essential Dynamics, ADMET, DFT, Synthesis, Anti-proliferative, and Apoptotic Evaluations of a New Anti-VEGFR-2 Nicotinamide Analogue.
Eissa IH; Elkaeed EB; Elkady H; Yousef RG; Alsfouk BA; Elzahabi HSA; Ibrahim IM; Metwaly AM; Husein DZ
Curr Pharm Des; 2023; 29(36):2902-2920. PubMed ID: 38031271
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
6. A Theobromine Derivative with Anticancer Properties Targeting VEGFR-2: Semisynthesis, in silico and in vitro Studies.
Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk AA; Husein DZ; Ibrahim IM; Radwan MM; Metwaly AM
ChemistryOpen; 2023 Oct; 12(10):e202300066. PubMed ID: 37803417
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects.
Elkaeed EB; Yousef RG; Elkady H; Gobaara IMM; Alsfouk BA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889478
[TBL] [Abstract][Full Text] [Related]
8. New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies.
Elkady H; Abuelkhir AA; Rashed M; Taghour MS; Dahab MA; Mahdy HA; Elwan A; Al-Ghulikah HA; Elkaeed EB; Ibrahim IM; Husein DZ; Metwaly A; Eissa IH
Comput Biol Chem; 2023 Dec; 107():107958. PubMed ID: 37714080
[TBL] [Abstract][Full Text] [Related]
9. Exploring the anticancer properties of a new nicotinamide analogue: Investigations into in silico analysis, antiproliferative effects, selectivity, VEGFR-2 inhibition, apoptosis induction, and migration suppression.
Eissa IH; Yousef RG; Sami M; Elkaeed EB; Alsfouk BA; Ibrahim IM; Husein DZ; Elkady H; Metwaly AM
Pathol Res Pract; 2023 Dec; 252():154924. PubMed ID: 37956639
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
Alanazi MM; Eissa IH; Alsaif NA; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Elkady H; Elwan A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1760-1782. PubMed ID: 34340610
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
12. Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies.
Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk BA; Husein DZ; Asmaey MA; Ibrahim IM; Metwaly AM
Pathol Res Pract; 2023 Nov; 251():154894. PubMed ID: 37857034
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
14. New theobromine derivatives inhibiting VEGFR-2: design, synthesis, antiproliferative, docking and molecular dynamics simulations.
Mahdy HA; Elkady H; Taghour MS; Elwan A; Dahab MA; Elkady MA; Elsakka EG; Elkaeed EB; Alsfouk BA; Ibrahim IM; Eissa IH; Metwaly AM
Future Med Chem; 2023 Jul; 15(14):1233-1250. PubMed ID: 37466069
[No Abstract] [Full Text] [Related]
15. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
[TBL] [Abstract][Full Text] [Related]
16. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
17. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
18. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
19. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
20. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and
Elkady H; Elwan A; El-Mahdy HA; Doghish AS; Ismail A; Taghour MS; Elkaeed EB; Eissa IH; Dahab MA; Mahdy HA; Khalifa MM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):397-410. PubMed ID: 34961427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
